Status:
RECRUITING
Prevention of Vasospasm in SAH Through CSF Treatment
Lead Sponsor:
Medical University Innsbruck
Conditions:
Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Aneurysmal
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
The pathophysiological mechanisms of aneurysmal subarachnoid haemorrhage (aSAH) involve early brain injury (EBI) and delayed cerebral ischemia (DCI). Several mechanisms contribute to EBI pathogenesis...
Detailed Description
Aneurysmal subarachnoid haemorrhage (aSAH) is associated with high morbidity and mortality with an incidence of 5-9 per 100,000 population. The incidence of aSAH peaks amongst those of 40-60 years1; a...
Eligibility Criteria
Inclusion
- Age: \>18, \<90
- SAH HH 3 - 5
- Cerebral saccular Aneurysm
- Digital subtraction angiography prior to aneurysm repair
- Aneurysm repair within 72h
- Modified Fisher Grade 3+4
- Presence of aneurysm needing treatment (clipping or coiling)
- Treatment within 24 hours of symptom onset
- External ventricular drain (clinical need)
Exclusion
- Non-aneurysmal SAH
- SAH HH\<3
- Extensive intraventricular haemorrhage (unable to obtain CSF without massive aspiration of clotted blood)
- Contraindication for digital subtraction angiography
- Aneurysm repair \>72h after rupture
- Signs of radiographic vasospasm upon diagnosis
- Presence of systemic or CSF infection
- Contraindication for oral Nimodipin
- Pregnancy
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04490161
Start Date
January 1 2020
End Date
February 1 2025
Last Update
November 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Innsbruck
Innsbruck, Tyrol, Austria, 6020